Agenus (NASDAQ:AGEN) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07), Bloomberg Earnings reports. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.30 million. Agenus’s revenue for the quarter was up 48.2% compared to the same quarter last year.
Shares of Agenus (AGEN) opened at $5.40 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. The stock has a market cap of $587.32, a P/E ratio of -4.89 and a beta of 1.50. Agenus has a 12-month low of $3.20 and a 12-month high of $6.19.
AGEN has been the subject of a number of research analyst reports. BidaskClub lowered shares of Agenus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, January 9th. Finally, ValuEngine upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Agenus currently has an average rating of “Buy” and an average price target of $5.81.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.